| Autor: |
Kessel S; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Cribbes S; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Déry O; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Kuksin D; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Sincoff E; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Qiu J; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA., Chan LL; 1 Department of Technology R&D, Nexcelom Bioscience LLC, Lawrence, MA, USA. |
| Abstrakt: |
Oncologists have investigated the effect of protein or chemical-based compounds on cancer cells to identify potential drug candidates. Traditionally, the growth inhibitory and cytotoxic effects of the drugs are first measured in 2D in vitro models, and then further tested in 3D xenograft in vivo models. Although the drug candidates can demonstrate promising inhibitory or cytotoxicity results in a 2D environment, similar effects may not be observed under a 3D environment. In this work, we developed an image-based high-throughput screening method for 3D tumor spheroids using the Celigo image cytometer. First, optimal seeding density for tumor spheroid formation was determined by investigating the cell seeding density of U87MG, a human glioblastoma cell line. Next, the dose-response effects of 17-AAG with respect to spheroid size and viability were measured to determine the IC 50 value. Finally, the developed high-throughput method was used to measure the dose response of four drugs (17-AAG, paclitaxel, TMZ, and doxorubicin) with respect to the spheroid size and viability. Each experiment was performed simultaneously in the 2D model for comparison. This detection method allowed for a more efficient process to identify highly qualified drug candidates, which may reduce the overall time required to bring a drug to clinical trial. |
